肿瘤分子靶向治疗疗效及不良反应

Therapeutic response and adverse reaction of molecular targeted therapy of tumor

目前已有10余种肿瘤分子靶向药物进入临床应用，按药物本身性质可以分成两大类：单克隆抗体及小分子化合物，后者包括酪氨酸激酶抑制剂及蛋白酶小体抑制剂等，在白血病、淋巴瘤以及乳腺癌、非小细胞肺癌、结直肠癌等肿瘤中均取得了令人满意的疗效。临床试验证实许多靶向药物联合治疗及联合放化疗可以取得较单药治疗更为明显的疗效，而靶向药物的不良反应较轻，可以耐受。

Over 10 agents have been accepted in molecular targeted therapy for tumor, which can be categorized into two groups： monoclonal antibody and little molecular compounds including tyrosine kinase inhibitor and proteasome inhibitor. They are proved effective in the treatment of leukaemia, lymphoma and solid tumors like breast cancer, non-small cell lung cancer and colorectal cancer. Therapeutic alliance of targeted drugs and combination with chemoradiotherapy can be more successful. Generally, adverse reactions are gentle and can be well tolerated.